Warsaw - Delayed Quote PLN

Selvita S.A. (SLV.WA)

67.00 -1.00 (-1.47%)
At close: 3:32 PM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in PLN.
NameTitlePayExercisedYear Born
Mr. Boguslaw Stanislaw Sieczkowski M.B.A. Chairman of Management Board & CEO 1.1M -- --
Dr. Milosz Kazimierz Gruca Ph.D. Chief Commercial Officer, Executive VP & Vice President of Management Board 1.09M -- --
Mr. Dariusz Tomasz Kurdas Chief Financial Officer & Member of the Management Board 590.72k -- --
Dr. Miroslawa Monika Zydron Ph.D. COO & Member of the Management Board 644.19k -- --
Mr. Dawid Patryk Radziszewski General Counsel & Member of the Management Board 672.21k -- --
Dr. Adrijana Vinter Global Head of Drug Discovery & Member of the Management Board 1.25M -- --

Selvita S.A.

Bobrzynskiego 14
Kraków, 30-348
Poland
48 122 97 47 00 https://selvita.com
Sector: 
Healthcare
Full Time Employees: 
886

Description

Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, inflammation, and fibrosis. In addition, the company provides drug development services, including development, validation, and transfer; quality control; small molecules analytical testing; stability testing; elemental impurities testing; pharmaceutical impurities identification, determination, and testing; nitrosamines determination and testing; pyrrolizidine alkaloids determination and testing; cleaning validation; bioequivalence; analytical support and equipment; ICH Q6B testing; physicochemical properties determination; binding properties and potency assays; therapeutic proteins production and development services. Further, it offers research and development services in the areas of agrochemistry analytical support, flavor and fragrance, and chemotypes. The company has a collaboration agreement with The University of Oxford to advance potential therapeutics for Parkinson's disease. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Corporate Governance

Selvita S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events